Age-related macular degeneration (AMD) represents a significant and growing public health challenge, primarily affecting individuals over the age of 50. The condition targets the macula, the central part of the retina responsible for sharp, detailed vision essential for activities like reading, driving, and recognizing faces. AMD exists in two primary forms: dry AMD, which is more common and involves the thinning of macular tissue and the accumulation of drusen, and wet AMD. Wet AMD, while less prevalent, accounts for the majority of severe vision loss associated with the disease. It is characterized by the rapid growth of abnormal, leaky blood vessels beneath the macula, a process driven by vascular endothelial growth factor (VEGF). These aberrant vessels cause fluid and blood to leak into the retinal layers, leading to rapid and often irreversible damage to photoreceptor cells and subsequent vision distortion or loss. The progressive nature of wet AMD necessitates timely and effective intervention to halt or slow disease progression and preserve remaining vision.

The advent of anti-VEGF therapies revolutionized the treatment paradigm for wet AMD, transforming it from a condition with limited therapeutic options to one where significant vision preservation and even improvement is achievable. Bevacizumab, originally approved for cancer treatment, emerged as an early and effective off-label treatment for wet AMD due to its potent ability to inhibit VEGF. Its efficacy in stabilizing vision and reducing leakage from abnormal blood vessels quickly established it as a standard of care, despite its off-label status for this indication. Subsequently, ranibizumab (Lucentis) was specifically approved for wet AMD, followed by aflibercept (Eylea), both designed as targeted anti-VEGF agents for ocular use. These therapies are typically administered via intravitreal injections directly into the eye, requiring repeated treatments to maintain their therapeutic effect. The development of biosimil versions of these established treatments, like Lytenava, aims to increase competition, potentially lower costs, and broaden patient access to these sight-saving interventions.

The economic burden of AMD, particularly wet AMD, is substantial, encompassing direct medical costs for treatment and indirect costs related to loss of productivity and increased caregiving needs. As the global population ages, the prevalence of AMD is projected to rise, further exacerbating these economic and social impacts. The development and approval of biosimil medications like Lytenava are critical components of healthcare policy aimed at managing these rising costs while ensuring continued access to high-quality treatments. Biosimil development requires rigorous scientific evaluation to demonstrate comparability to the reference product, ensuring that patients receive a safe and effective alternative. The successful integration of biosimil bevacizumab into the treatment landscape for wet AMD holds the promise of not only alleviating individual suffering but also contributing to the long-term sustainability of healthcare systems tasked with managing this chronic and debilitating condition.